Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses (Q43092892)
Jump to navigation
Jump to search
scientific article published in September 2010
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses |
scientific article published in September 2010 |
Statements
1 reference
Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses (English)
1 reference
Jeffrey L Lennox
1 reference
Edwin Dejesus
1 reference
Daniel S Berger
1 reference
Richard B Pollard
1 reference
Jose Valdez Ramalho Madruga
1 reference
Jing Zhao
1 reference
Hong Wan
1 reference
Christopher L Gilbert
1 reference
Hedy Teppler
1 reference
Anthony J Rodgers
1 reference
Richard J O Barnard
1 reference
Michael D Miller
1 reference
Mark J Dinubile
1 reference
Bach-Yen Nguyen
1 reference
Randi Leavitt
1 reference
Peter Sklar
1 reference
STARTMRK Investigators
1 reference
1 September 2010
1 reference
1 reference
1 reference